Barcelona, September 18th
PROGRAMME
09:00-09:10 Welcome & Introduction
Cleofé Romagosa, TBD, Claudia Valverde
Hospital Univ. Vall d'Hebron, Barcelona
09:10-09:55 SESSION 1. FOCUSING ON OUR RESEARCHERS: AN OVERVIEW OF GEIS-BUESA GRANTS
9:15-9:25 And the winner is... By Nieves Martínez,
Hospital Clínico Universitario de Santiago, Santiago de Compostela (A Coruña)
9:25-9:35 Buesa grant 2026: new award
9:35-9:45 Buesa grant 2024. Perfil epigenético de los osteosarcomas para un mejor pronóstico, diagnóstico y tratamiento.
Empar Mayordomo, Hospital Universitari i Politècnic La Fe, Valencia
9:55-10:40 SESSION 2. SARCOMA SUBTYPE HIGHLIGHTED: RHABDOMYOSARCOMA
Chairs: Cristina Mata, Gregorio Marañón General University Hospital, Madrid
Raquel Correa, Hospital Clínico Universitario Virgen de la Victoria, Málaga
10:00-10:15 Interactive clinical case
Borja González, Hospital Universitario Lucus Augusti, Lugo
10:15-10:30 Pathology insights
TBD.
10:30-10:45 Surgical challenges
Michiel van den Sande, Princess Máxima Center, Utrecht (The Netherlands)
10:45-11:00 New treatment opportunities
Lucy Metayer, Institut Gustave Roussy, Paris (France)
11:00-11:20 Discussion
11:20-11:40 Coffee Break
11:40-13:30 SESSION 3. LET’S IMPROVE: HOW TO OPTIMIZE WHAT WE ALREADY KNOW
Chairs: Anderson Cardozo, Hospital Universitario Vall d'Hebron, Barcelona
Isidro Gracia, Hospital Universitario de la Santa Creu i Sant Pau, Barcelona
11:45-12:00 What's the role of Nuclear Medicine in sarcoma in 2026?
Virginia Pubul, Hospital Clínico Universitario de Santiago, Santiago de Compostela (A Coruña)
12:00- 12:15 Integrated diagnosis. Tissue maps
José Manuel Morales, Hospital Universitario Virgen del Rocío, Seville
12:15-12:30 The Boom Birgminham consensus: TCG
Roberto Vélez, Hospital Vall d'Hebrón, Barcelona
12:30-12:45 Beyond resectability: Biology-Driven Surgical Salvage in Recurrent Sarcoma
Hugo Vasques, Instituto Português de Oncologia, Lisbon (Portugal)
12:45-13:00 Optimizing radiotherapy by age and tumor subtype
Iñigo San Miguel, Hospital Universitario de Salamanca, Salamanca
13:00-13:15 Challenging the treatment sequence in GIST
Bruno Vicenzi, Università Campus Bio-Medico di Roma, Rome (Italy)
13:15-13:30 Discussion
13:35-14:10: Lunch break
14:15-15:20 SESSION 4. THE PATIENT'S VOICE
Chairs: Aurelio Vicente, APSATUR,
María Teresa Deus, ASARGA
14:15-14:30 Patient involvement opportunities coming from EU
Claudia Valverde, Hospital Vall d 'Hebrón, Barcelona
14:30-14:45 Examples of success
Natalia Fernández, ASARGA
14:45-15:15 Round table discussion
Discussants: Patients' representatives of Asociación VYDA, FMPJC, APSATUR, ASARGA, Asociación Íker, FEPNC, Juegaterapia, AECC,
Chordoma Foundation, Fundación Aladina
15:20-16:35 SESSION 5. FOCUSING ON PATHOLOGY AND GENETICS
Chairs: Carmen Gómez, Hospital Universitario Miguel Servet, Zaragoza
J. Alejandro Pérez Fidalgo, Hospital Clínico Univerisitario de Valencia
15:20-15:35 WHO 2026: Which are the main changes?
Judith Bovée, Leiden University Medical Center, The Netherlands
15:35-15:50 WHO 2026: What does it mean for us?
Shreyas Patel, University of Texas MD Anderson Cancer Center, Houston (Texas), USA
15:50-16:05 NGS in sarcomas: who and when to test and what to do with incidental findings?
Willian Tap, Memorial Sloan Kettering Cancer Center, New York (NY), USA
16:05-16:20 Genetic counseling in sarcoma: are we missing patients?
Judith Balmaña, Hospital Vall d'Hebrón, Barcelona
16:20-16:35 Discussion
16:35-16:50 Coffee break
16:50-17:55 SESSION 6. CHALLENGING ISSUES
Chairs: Fina Cruz, Hospital Universitario de Canarias, La Laguna (Santa Cruz de Tenerife)
José Manuel Asencio, Gregorio Marañón General University Hospital, Madrid
16:55-17:10 ADCs and new immunotherapy options for dummies
Beatriz Jiménez, Hospital Vall d 'Hebrón, Barcelona
17:10-17:25 Looking into the future:ADCs and immunotherapy in advanced disease
Robert Maki, Memorial Sloan Kettering Cancer Center, New York (NY), USA
17:25-17:40 Looking into the future: Any role for immunotherapy in localized disease?
Salvatore Provenzano, Istituto Nazionale dei Tumori, Milan (Italy)
17:40-17:55 Discussion
17:55-18:00 FAREWELL
Cleofé Romagosa, Hospital Vall d 'Hebrón, Barcelona
Claudia Valverde, Hospital Vall d 'Hebrón, Barcelona
Venue:
Salón de Actos del Pabellón Docente
Hospital Univ. Vall d'Hebron
Pº Vall d'Hebron, 119-129
Barcelona
Language:
English and Spanish. Simultaneous translation will be available.
Registration Fee:
Until June, 30th: 450€
From July, 1st to August, 15th: 550€
From August, 16th: 650€
Technical Secretariat:
Grupo Español de Investigación en Sarcoma
E-mail: eventos(at)grupogeis.org
Telephone: (+34) 912 866 807